Johnson & Johnson will sell or spinout its $20B DePuy Synthes orthopedics business, and that tell-all number tells you absolutely everything you need to know about the current landscape.
J&J MedTech (fka DePuy-Synthes) is shrinking to grow faster, shifting its heavy capital toward higher-growth, sexier margins like cardiovascular tech and advanced robotics.
Meanwhile, they are preparing to hand the keys of the world’s largest legacy orthopedic portfolio over to Namal Nawana to steer as a standalone entity.
But let’s cut through the corporate PR gloss about "strategic operational focus" and talk about the elephant in the OR. Independence would undoubtedly be a operational reset, but the real question keeping everyone up at night isn’t about independence—it’s whether DePuy Spine can actually grow at anything other than 0% per year.
The Bleeding Market Share
Here is the harder truth that nobody in New Brunswick wants to shout from the rooftops: DePuy Spine has been bleeding market share for years. They didn't just slip; they cratered. They went from a staggering 55% market dominance down to roughly 31%.
That is not a macroeconomic market problem. That is pure execution.
When ...
